FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2486286843> ?p ?o ?g. }

• W2486286843 abstract "Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LABackground: Endometrial cancer is the most common malignancy of the female reproductive tract and the third most common cause of death from women's cancer. Risk factors of endometrial cancer include high levels of estrogen, obesity, diabetes mellitus, breast cancer, long term use of tamoxifen, late menopause, high blood pressure, and increasing age. Although the exact mechanisms in endometrial carcinogenesis due to chronic exposure are unclear, it is though that the pro-proliferative and DNA-damaging effects of estrogen and its metabolites, related with and insufficient counterbalance by progesterone, promote the hyper-proliferation and transformation of cells. Selective progesterone receptor modulator (SPRM) is an agent that acts on the progesterone receptor. Ulipristal acetate (UA) is one of SPRM and other SPRM, such as Mifepristone, showed inhibitory effect on various endometrial cancer cell lines. UA has been available as an emergency contraception and a treatment for uterine leiomyoma. The effect of UA on leiomyoma is decreasing neovascularization, proliferation, and viability.Objective: This study was undertaken to investigate antitumor effect of UA and to explore the effect of combination treatment with chemotherapy drug in endometrial cancer.Method: Inhibitory concentration (IC), proliferation assay, and migration assay were performed using Ishikawa, HEC-1-A, HEC-1-B, and/or patient-derived primary cancer cells (PCC). Different concentration of UA were treated in endometrial cancer cell lines and PCCs for the each assay. The CellTiter-Glo assay were performed to investigate IC50 in cell lines and PCCs. Crystal violet staining and wound healing assay were performed to examine cell proliferation and migration.Results: UA inhibited cell viability of endometrial cancer cell lines and PCCs at high concentration, most abviously 10uM in dose-dependent manner. In combination treatment assay with paclitaxel, UA showed synergistic anti-tumor effect with low-dose of paclitaxel on cell lines and PCCs.Conclusions: We showed that combination treatment of UA and paclitaxel effectively than single treatment by low dosage. In summary, we are actively exploring new effective applicable drugs for endometrial cancer, and our data suggest that UA may have therapeutic value with chemo-combination treatment of patients with endometrial cancer.Citation Format: Ha-Young Lee, A Ra Ko, Dong-Woo Kang, Yu-Seon Kim, Su-Min Kim, Tae-Wook Kang, Shin-Wha Lee, Yong-Man Kim. Anti-tumor effect of selective progesterone receptor modulator (ulipristal acetate) on endometrial cancer cell lines. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1191." @default.
• W2486286843 created "2016-08-23" @default.
• W2486286843 creator A5001632450 @default.
• W2486286843 creator A5036089590 @default.
• W2486286843 creator A5037553565 @default.
• W2486286843 creator A5040573037 @default.
• W2486286843 creator A5053719602 @default.
• W2486286843 creator A5058475655 @default.
• W2486286843 creator A5069016269 @default.
• W2486286843 creator A5088879960 @default.
• W2486286843 date "2016-07-15" @default.
• W2486286843 modified "2023-09-25" @default.
• W2486286843 title "Abstract 1191: Anti-tumor effect of selective progesterone receptor modulator (ulipristal acetate) on endometrial cancer cell lines" @default.
• W2486286843 doi "https://doi.org/10.1158/1538-7445.am2016-1191" @default.
• W2486286843 hasPublicationYear "2016" @default.
• W2486286843 type Work @default.
• W2486286843 sameAs 2486286843 @default.
• W2486286843 citedByCount "0" @default.
• W2486286843 crossrefType "proceedings-article" @default.
• W2486286843 hasAuthorship W2486286843A5001632450 @default.
• W2486286843 hasAuthorship W2486286843A5036089590 @default.
• W2486286843 hasAuthorship W2486286843A5037553565 @default.
• W2486286843 hasAuthorship W2486286843A5040573037 @default.
• W2486286843 hasAuthorship W2486286843A5053719602 @default.
• W2486286843 hasAuthorship W2486286843A5058475655 @default.
• W2486286843 hasAuthorship W2486286843A5069016269 @default.
• W2486286843 hasAuthorship W2486286843A5088879960 @default.
• W2486286843 hasConcept C121608353 @default.
• W2486286843 hasConcept C126322002 @default.
• W2486286843 hasConcept C134018914 @default.
• W2486286843 hasConcept C2777088508 @default.
• W2486286843 hasConcept C2777176818 @default.
• W2486286843 hasConcept C2777486506 @default.
• W2486286843 hasConcept C2778826759 @default.
• W2486286843 hasConcept C2779076696 @default.
• W2486286843 hasConcept C2779234561 @default.
• W2486286843 hasConcept C2908647359 @default.
• W2486286843 hasConcept C2986817661 @default.
• W2486286843 hasConcept C502942594 @default.
• W2486286843 hasConcept C530470458 @default.
• W2486286843 hasConcept C54355233 @default.
• W2486286843 hasConcept C71924100 @default.
• W2486286843 hasConcept C84606932 @default.
• W2486286843 hasConcept C86803240 @default.
• W2486286843 hasConcept C98717036 @default.
• W2486286843 hasConcept C99454951 @default.
• W2486286843 hasConceptScore W2486286843C121608353 @default.
• W2486286843 hasConceptScore W2486286843C126322002 @default.
• W2486286843 hasConceptScore W2486286843C134018914 @default.
• W2486286843 hasConceptScore W2486286843C2777088508 @default.
• W2486286843 hasConceptScore W2486286843C2777176818 @default.
• W2486286843 hasConceptScore W2486286843C2777486506 @default.
• W2486286843 hasConceptScore W2486286843C2778826759 @default.
• W2486286843 hasConceptScore W2486286843C2779076696 @default.
• W2486286843 hasConceptScore W2486286843C2779234561 @default.
• W2486286843 hasConceptScore W2486286843C2908647359 @default.
• W2486286843 hasConceptScore W2486286843C2986817661 @default.
• W2486286843 hasConceptScore W2486286843C502942594 @default.
• W2486286843 hasConceptScore W2486286843C530470458 @default.
• W2486286843 hasConceptScore W2486286843C54355233 @default.
• W2486286843 hasConceptScore W2486286843C71924100 @default.
• W2486286843 hasConceptScore W2486286843C84606932 @default.
• W2486286843 hasConceptScore W2486286843C86803240 @default.
• W2486286843 hasConceptScore W2486286843C98717036 @default.
• W2486286843 hasConceptScore W2486286843C99454951 @default.
• W2486286843 hasLocation W24862868431 @default.
• W2486286843 hasOpenAccess W2486286843 @default.
• W2486286843 hasPrimaryLocation W24862868431 @default.
• W2486286843 hasRelatedWork W2000850974 @default.
• W2486286843 hasRelatedWork W2006482008 @default.
• W2486286843 hasRelatedWork W2009889499 @default.
• W2486286843 hasRelatedWork W2015204910 @default.
• W2486286843 hasRelatedWork W2045728890 @default.
• W2486286843 hasRelatedWork W2060440438 @default.
• W2486286843 hasRelatedWork W2075537829 @default.
• W2486286843 hasRelatedWork W2076879817 @default.
• W2486286843 hasRelatedWork W2080322268 @default.
• W2486286843 hasRelatedWork W2102356191 @default.
• W2486286843 hasRelatedWork W2104216849 @default.
• W2486286843 hasRelatedWork W2131622214 @default.
• W2486286843 hasRelatedWork W2165943564 @default.
• W2486286843 hasRelatedWork W2324859338 @default.
• W2486286843 hasRelatedWork W2409091450 @default.
• W2486286843 hasRelatedWork W2468281002 @default.
• W2486286843 hasRelatedWork W2786139684 @default.
• W2486286843 hasRelatedWork W2887811349 @default.
• W2486286843 hasRelatedWork W2896550137 @default.
• W2486286843 hasRelatedWork W2947939944 @default.
• W2486286843 isParatext "false" @default.
• W2486286843 isRetracted "false" @default.
• W2486286843 magId "2486286843" @default.
• W2486286843 workType "article" @default.